Wildriss Viranaicken

Title: Wildriss Viranaicken: Innovator in Vaccine Development

Introduction

Wildriss Viranaicken is a notable inventor based in Sainte Clotilde la Reunion, France. He has made significant contributions to the field of vaccine development, particularly in relation to the Zika virus. His innovative work focuses on creating vaccine compositions that utilize an attenuated mutant Zika virus.

Latest Patents

Viranaicken holds a patent for vaccine compositions comprising an attenuated mutant Zika virus. This invention introduces mutations at specific positions that eliminate the N-glycosylation site on the E protein of the epidemic strain. This modification is crucial as it prevents the generation of auto-antibodies that can lead to Guillain-Barre syndrome. Additionally, the inventors have engineered further mutations that significantly reduce the cytopathic effects of the virus while maintaining its ability to produce high titers. Specifically, the patent relates to an attenuated mutant Zika virus that includes a protein E of the epidemic strain, wherein at least one amino acid residue at positions 152, 156, or 158 is mutated.

Career Highlights

Throughout his career, Wildriss Viranaicken has worked with esteemed institutions such as Inserm (Institut National de la Santé et de la Recherche Médicale) and Université de la Réunion Saint Denis. His work in these organizations has contributed to advancements in medical research and vaccine development.

Collaborations

Viranaicken has collaborated with notable colleagues, including Philippe Despres and Gilles Gadea. These partnerships have enhanced the research and development of innovative vaccine solutions.

Conclusion

Wildriss Viranaicken's contributions to vaccine development, particularly regarding the Zika virus, highlight his role as an influential inventor in the field. His patented innovations and collaborations with leading institutions underscore the importance of his work in advancing public health.